AACR 2021 | Intratumoral injection of SYNB1891
Filip Janku, MD, PhD, MD Anderson Cancer Center, TX, discusses findings of a first-in-human study (NCT04167137) of intratumoral injection of SYNB1891 in patients with refractory advanced solid tumors or lymphoma. SYNB1891 is a live, modified strain of probiotic E.Coli Nissle which has been engineered to produce cyclic dinucleotides, leading to stimulator of interferon genes (STING) pathway activation in phagocytic antigen-presenting cells. The study reported that intratumoral injection of SYNB1891 as monotherapy is safe and well-tolerated and demonstrated evidence of STING pathway target engagement. The second arm of the study will explore SYNB1891 in combination with atezolizumab. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Filip Janku, MD, PhD, has received research support from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Astex, Agios, Bicara, Bioxcel Therapeutics, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Merck, Ideaya Biosciences, JS Innophram, Synthorx, Sanofi, SpringBank Pharmaceuticals, SQZ Biotechnologies, Synlogic, FujiFilm Pharmaceuticals, Sotio, Lilly, Puretech Health and Novellus; is or has been on the Scientific Advisory Boards for Bicara, Illumina, Ideaya Biosciences, IFM Therapeutics, Synlogic, Sotio, Puretech Health, Petra Pharma, Novellus and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology.
